Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2017-02-23

FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for Hikma Pharmaceuticals USA Inc. to market fluphenazine decanoate, a long-acting injectable antipsychotic used to trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Fluphenazine decanoate (Fluphenazine decanoate)

Snippet

SUPPL AP for FLUPHENAZINE DECANOATE (FLUPHENAZINE DECANOATE)